XML 96 R14.htm IDEA: XBRL DOCUMENT
v3.22.4

Inventory | 12 Months Ended
--- | ---
Dec. 31, 2022
Inventory Disclosure [Abstract] |
Inventory |
Note 6: | Inventory
The components of inventory are summarized as follows:
|  | As of December 31,
(In millions) |  | 2022 |  | 2021
Raw materials |  | $ | 413.2 |  |  | $ | 349.6 |
Work in process(1) |  | 751.9 |  |  | 814.0 |
Finished goods |  | 200.4 |  |  | 187.9 |
Total inventory |  | $ | 1,365.5 |  |  | $ | 1,351.5 |
Balance Sheet Classification: |  |  |  |
Inventory |  | $ | 1,344.4 |  |  | $ | 1,351.5 |
Investments and other assets |  | 21.1 |  |  | — |
Total inventory |  | $ | 1,365.5 |  |  | $ | 1,351.5 |
(1) Work in process inventory as of December 31, 2022, includes approximately $89.8 million related to LEQEMBI. Long-term inventory is included in investments and other assets in our consolidated balance sheets. Inventory amounts written down as a result of excess, obsolescence or unmarketability are charged to cost of sales, and totaled $336.2 million, $167.6 million and $26.6 million for the years ended December 31, 2022, 2021 and 2020, respectively. Inventory Write-Offs In April 2022 the Centers for Medicare and Medicaid Services (CMS) released the final National Coverage Decision (NCD) for the class of anti-amyloid treatments in Alzheimer's disease, including ADUHELM. The final NCD confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $275.0 million of inventory related to ADUHELM, as a result of this CMS decision, which was recognized in cost of sales within our consolidated statements of income for the year ended December 31, 2022. We have recognized approximately $136.0 million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our consolidated statements of income for the year ended December 31, 2022. During the fourth quarter of 2021 we wrote-off approximately $120.0 million of inventory in excess of forecasted demand related to ADUHELM, which was recognized in cost of sales within our consolidated statements of income for the year ended December 31, 2021. We have recognized approximately $59.0 million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our consolidated statements of income for the year ended December 31, 2021. As of December 31, 2022, the carrying value of our ADUHELM inventory was immaterial. As of December 31, 2021, we had approximately $223.0 million of ADUHELM inventory. For additional information please read Note 19, Collaborative and Other Relationships, to these consolidated financial statements.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -URI https://asc.fasb.org/topic&trid=2126998 + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration